Physician profile
John D Ayers
NPI 1477540821
$1,995.80
in general payments reported to CMS, 2019-2025
8 companies · $68.49 in 2025
The $68.49 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.07 · 2021: $11.92 · 2022: $135 · 2023: $15.94 · 2024: $1,742 · 2025: $68.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,650 · Food and Beverage: $92.25 · Education: $84.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,650.00 |
| Food and Beverage | $92.25 |
| Education | $84.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,807.76 | 2024-2025 | Imfinzi |
| Ge Healthcare | $135.13 | 2022 | |
| Sysmex America, INC. | $22.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.94 | 2023 | Abilify |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Pfizer INC. | $2.98 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.